Navigation Links
BioMS Medical to participate in panel session at Bio International Convention 2009
Date:5/14/2009

- "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration" -

Toronto Stock Exchange Symbol: MS

EDMONTON, May 14 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Richard Brown, Vice President, Commercial Development, BioMS Medical and Mr. Jack Tupman, Senior Director, Corporate Business Development, Eli Lilly and Company, will take part in a Technology Transfer/Licensing session at the BIO International Convention 2009 in Atlanta, Georgia entitled "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration."

Also participating in the panel session will be Mr. Nitin Kaushal, Director, Healthcare Investment Banking, Desjardins Securities and Mr. Jeremy Webster, Senior VP & Director Deloitte & Touche, LLP. The moderator for the session will be Ms. Cheryl Reicin, Partner, Torys LLP.

    WHEN:     Thursday May 21st at 8:00am (Eastern Time)

    WHERE:    Room B316, Georgia World Congress Center, Atlanta, Georgia

    BioMS Medical will also provide a corporate presentation at the Business
Forum at 9:40am (Eastern Time) on Wednesday May 20th.

    About BIO International Convention
    ----------------------------------
    The BIO International Convention, hosted by the Biotechnology Industry
Organization, is the largest global event for the biotechnology industry and
attracts the biggest names in biotech, offers key networking and partnering
opportunities, and provides insights and inspiration on major trends affecting
the industry. For more information visithttp://convention.bio.org/.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. BioMS Medical to present at Alberta Economic Forum in Geneva
3. BioMS Medical to present at BioFinance 2009
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical Announces 2008 Year End Results
7. BioMS Medical warrant extension
8. BioMS Medical to present at BIO CEO and Investor Conference
9. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
10. BioMS Medical recognized at Scrip Awards 2008
11. BioMS Medical Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):